 Corey Montgomery
Concepts (178)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 5 | 2019 | 72 | 1.840 |
Why?
| | Bone Neoplasms | 6 | 2023 | 184 | 1.440 |
Why?
| | Osteomyelitis | 2 | 2017 | 125 | 0.870 |
Why?
| | Muscle Neoplasms | 2 | 2019 | 16 | 0.770 |
Why?
| | Soft Tissue Injuries | 2 | 2019 | 17 | 0.670 |
Why?
| | Tertiary Care Centers | 2 | 2019 | 85 | 0.640 |
Why?
| | Cultural Diversity | 1 | 2019 | 36 | 0.630 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2018 | 3 | 0.620 |
Why?
| | Orthopedics | 1 | 2019 | 53 | 0.600 |
Why?
| | Orthopedic Procedures | 1 | 2019 | 71 | 0.600 |
Why?
| | Minority Groups | 1 | 2019 | 135 | 0.590 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 118 | 0.590 |
Why?
| | Coitus | 1 | 2017 | 18 | 0.560 |
Why?
| | Abscess | 1 | 2017 | 36 | 0.560 |
Why?
| | Students, Medical | 1 | 2019 | 159 | 0.550 |
Why?
| | Muscular Diseases | 2 | 2014 | 63 | 0.550 |
Why?
| | Amputation, Traumatic | 1 | 2017 | 7 | 0.540 |
Why?
| | Drainage | 1 | 2017 | 87 | 0.540 |
Why?
| | Prosthesis Failure | 1 | 2017 | 111 | 0.540 |
Why?
| | Hip Prosthesis | 1 | 2017 | 71 | 0.530 |
Why?
| | Obesity | 2 | 2018 | 1162 | 0.520 |
Why?
| | Agkistrodon | 1 | 2016 | 3 | 0.510 |
Why?
| | Antivenins | 1 | 2016 | 9 | 0.500 |
Why?
| | Snake Bites | 1 | 2016 | 14 | 0.500 |
Why?
| | Patient Transfer | 1 | 2016 | 99 | 0.460 |
Why?
| | Diabetes Complications | 2 | 2014 | 122 | 0.460 |
Why?
| | Internship and Residency | 1 | 2019 | 448 | 0.440 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2017 | 266 | 0.420 |
Why?
| | Arthritis, Infectious | 1 | 2013 | 43 | 0.400 |
Why?
| | Retrospective Studies | 8 | 2019 | 6607 | 0.390 |
Why?
| | Diagnostic Imaging | 1 | 2013 | 181 | 0.370 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 46 | 0.340 |
Why?
| | Humans | 24 | 2023 | 52483 | 0.340 |
Why?
| | Male | 17 | 2019 | 26761 | 0.330 |
Why?
| | Osteosarcoma | 3 | 2016 | 44 | 0.330 |
Why?
| | Magnetic Resonance Imaging | 5 | 2017 | 1546 | 0.310 |
Why?
| | Female | 15 | 2019 | 28171 | 0.300 |
Why?
| | Anterior Cruciate Ligament | 1 | 2008 | 10 | 0.290 |
Why?
| | Fracture Fixation, Internal | 1 | 2008 | 42 | 0.290 |
Why?
| | Arthroscopy | 1 | 2008 | 41 | 0.290 |
Why?
| | Femoral Fractures | 1 | 2008 | 41 | 0.280 |
Why?
| | Sex Distribution | 2 | 2019 | 137 | 0.280 |
Why?
| | Postoperative Complications | 2 | 2018 | 1068 | 0.260 |
Why?
| | Accidental Falls | 1 | 2008 | 105 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 5 | 2017 | 1165 | 0.260 |
Why?
| | Child | 5 | 2017 | 7248 | 0.240 |
Why?
| | Adult | 8 | 2019 | 14161 | 0.230 |
Why?
| | Bone Regeneration | 2 | 2016 | 70 | 0.220 |
Why?
| | Osteoblastoma | 1 | 2023 | 2 | 0.210 |
Why?
| | Osteoma, Osteoid | 1 | 2023 | 4 | 0.210 |
Why?
| | Cisplatin | 2 | 2016 | 285 | 0.200 |
Why?
| | Intensive Care Units | 2 | 2016 | 243 | 0.200 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 285 | 0.200 |
Why?
| | United States | 3 | 2019 | 5192 | 0.200 |
Why?
| | Age Factors | 2 | 2017 | 1132 | 0.190 |
Why?
| | Middle Aged | 6 | 2019 | 13028 | 0.180 |
Why?
| | Infant, Newborn | 3 | 2023 | 2867 | 0.170 |
Why?
| | Adolescent | 5 | 2017 | 6739 | 0.170 |
Why?
| | Musculoskeletal System | 1 | 2019 | 16 | 0.160 |
Why?
| | Curettage | 1 | 2018 | 13 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2017 | 184 | 0.150 |
Why?
| | Bone Cements | 1 | 2018 | 30 | 0.150 |
Why?
| | Bone Transplantation | 1 | 2018 | 42 | 0.150 |
Why?
| | Diagnosis, Differential | 3 | 2023 | 1046 | 0.150 |
Why?
| | Aged | 5 | 2019 | 10121 | 0.150 |
Why?
| | Reoperation | 2 | 2017 | 465 | 0.150 |
Why?
| | Tibia | 1 | 2018 | 113 | 0.150 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 75 | 0.140 |
Why?
| | Femoral Neoplasms | 1 | 2017 | 8 | 0.140 |
Why?
| | Chondrosarcoma | 1 | 2017 | 12 | 0.140 |
Why?
| | Rotation | 1 | 2017 | 44 | 0.140 |
Why?
| | Survival Analysis | 1 | 2019 | 673 | 0.140 |
Why?
| | Tissue Transplantation | 1 | 2017 | 8 | 0.140 |
Why?
| | Posture | 1 | 2017 | 66 | 0.140 |
Why?
| | Amputees | 1 | 2017 | 9 | 0.140 |
Why?
| | Neurilemmoma | 1 | 2017 | 24 | 0.140 |
Why?
| | Wrist | 1 | 2017 | 15 | 0.130 |
Why?
| | Osteogenesis, Distraction | 2 | 2016 | 78 | 0.130 |
Why?
| | Femur | 1 | 2017 | 135 | 0.130 |
Why?
| | S100 Proteins | 1 | 2017 | 34 | 0.130 |
Why?
| | Calcification, Physiologic | 1 | 2017 | 42 | 0.130 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 58 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 649 | 0.130 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2017 | 25 | 0.130 |
Why?
| | Connexins | 1 | 2016 | 24 | 0.130 |
Why?
| | Breast Neoplasms | 3 | 2015 | 1212 | 0.130 |
Why?
| | Pelvis | 1 | 2017 | 69 | 0.130 |
Why?
| | Sweat Gland Neoplasms | 1 | 2016 | 22 | 0.130 |
Why?
| | Acute Disease | 1 | 2017 | 373 | 0.130 |
Why?
| | Infant | 2 | 2017 | 3733 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1222 | 0.130 |
Why?
| | Accidents, Traffic | 1 | 2017 | 90 | 0.130 |
Why?
| | Child, Preschool | 2 | 2017 | 4076 | 0.130 |
Why?
| | Child Health Services | 1 | 2017 | 79 | 0.130 |
Why?
| | Free Tissue Flaps | 1 | 2017 | 63 | 0.130 |
Why?
| | Databases, Factual | 1 | 2019 | 706 | 0.130 |
Why?
| | Hospitals, Rural | 1 | 2016 | 24 | 0.120 |
Why?
| | Upper Extremity | 1 | 2016 | 45 | 0.120 |
Why?
| | Age Distribution | 1 | 2016 | 174 | 0.120 |
Why?
| | Neoplasm Staging | 1 | 2018 | 772 | 0.120 |
Why?
| | Seasons | 1 | 2016 | 92 | 0.120 |
Why?
| | Imidazoles | 1 | 2016 | 124 | 0.120 |
Why?
| | Piperazines | 1 | 2016 | 118 | 0.120 |
Why?
| | Lower Extremity | 1 | 2016 | 100 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2016 | 78 | 0.120 |
Why?
| | Case-Control Studies | 1 | 2018 | 1201 | 0.120 |
Why?
| | Infarction | 1 | 2014 | 14 | 0.110 |
Why?
| | Thigh | 1 | 2014 | 34 | 0.110 |
Why?
| | Sex Factors | 1 | 2017 | 727 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2017 | 334 | 0.110 |
Why?
| | Necrosis | 1 | 2014 | 176 | 0.110 |
Why?
| | Disease Management | 1 | 2015 | 188 | 0.110 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 39 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2014 | 86 | 0.110 |
Why?
| | Bone and Bones | 1 | 2017 | 494 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2016 | 292 | 0.110 |
Why?
| | Osteolysis | 1 | 2014 | 75 | 0.100 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2014 | 90 | 0.100 |
Why?
| | Aged, 80 and over | 2 | 2018 | 3392 | 0.100 |
Why?
| | Brachytherapy | 1 | 2012 | 48 | 0.090 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 221 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2017 | 505 | 0.090 |
Why?
| | Cohort Studies | 1 | 2016 | 1542 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 2012 | 57 | 0.090 |
Why?
| | Epiphyses, Slipped | 1 | 2010 | 5 | 0.090 |
Why?
| | Osteochondrosis | 1 | 2010 | 6 | 0.090 |
Why?
| | Bone Diseases, Developmental | 1 | 2010 | 17 | 0.090 |
Why?
| | Time Factors | 2 | 2016 | 2968 | 0.090 |
Why?
| | Femur Head | 1 | 2010 | 25 | 0.090 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 338 | 0.080 |
Why?
| | Length of Stay | 1 | 2013 | 663 | 0.080 |
Why?
| | Fractures, Bone | 1 | 2010 | 107 | 0.080 |
Why?
| | Animals | 5 | 2016 | 13505 | 0.080 |
Why?
| | Multiple Myeloma | 2 | 2017 | 3049 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2016 | 5422 | 0.080 |
Why?
| | Knee Injuries | 1 | 2008 | 28 | 0.070 |
Why?
| | Proteomics | 1 | 2010 | 329 | 0.070 |
Why?
| | Young Adult | 2 | 2013 | 4329 | 0.060 |
Why?
| | Biopsy | 2 | 2017 | 605 | 0.060 |
Why?
| | Mice, Nude | 2 | 2016 | 265 | 0.060 |
Why?
| | Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2023 | 2 | 0.050 |
Why?
| | Polypyrimidine Tract-Binding Protein | 1 | 2023 | 11 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2023 | 60 | 0.050 |
Why?
| | Risk Factors | 1 | 2010 | 3889 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 1884 | 0.040 |
Why?
| | Myoblasts, Skeletal | 1 | 2017 | 10 | 0.030 |
Why?
| | Fibula | 1 | 2017 | 23 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 63 | 0.030 |
Why?
| | Tibial Fractures | 1 | 2017 | 33 | 0.030 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 94 | 0.030 |
Why?
| | Mitosis | 1 | 2017 | 88 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 124 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 154 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 185 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2016 | 220 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2016 | 220 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 582 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 285 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 454 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2017 | 665 | 0.030 |
Why?
| | Bone Screws | 1 | 2014 | 30 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2016 | 979 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 364 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 256 | 0.030 |
Why?
| | Mice | 2 | 2014 | 5949 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2014 | 552 | 0.020 |
Why?
| | Wound Infection | 1 | 2012 | 32 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 399 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 804 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 879 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2016 | 636 | 0.020 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2012 | 184 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 639 | 0.020 |
Why?
| | Quality of Life | 1 | 2015 | 879 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 1470 | 0.020 |
Why?
| | Proteome | 1 | 2010 | 171 | 0.020 |
Why?
| | Models, Biological | 1 | 2010 | 735 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2010 | 398 | 0.020 |
Why?
|
|
Montgomery's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|